The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: A meta-analysis

Journal of Clinical Hypertension

Volumn 20, Issue 5, 2018, Pages 902-907

  Du, Li Ping ^a   Cheng, Zhong Wei ^a   Zhang, Yu Xuan ^a   Li, Ying ^a   Mei, Dan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG COMBINATION; FIXED DOSE COMBINATION; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; META ANALYSIS; NEWCASTLE-OTTAWA SCALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT REFUSAL; AGED; BLOOD PRESSURE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 85051996849     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.13272     Document Type: Article

References (29)

1. Lewington S, Lacey B, Clarke R, et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern Med. 2016;176:524-532.
2. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441-450.
3. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-2260.
4. Peacock E, Krousel-Wood M. Adherence to antihypertensive therapy. Med Clin North Am. 2017;101:229-245.
5. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-2295.
6. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959-968.
7. Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich). 2008;10:20-26.
8. van Kleef ME, Spiering W. Hypertension: overly important but under-controlled. Eur J Prev Cardiol. 2017;24:36-43.
9. Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e5641.
10. Tung YC, Huang YC, Wu LS, et al. Medication compliance and clinical outcomes of fixed-dose combinations vs. combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment. J Clin Hypertens (Greenwich). 2017;19:983-989.
11. Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich). 2010;12:40-46.
12. Wong MC, Tam WW, Cheung CS, et al. Antihypertensive prescriptions over a 10-year period in a large Chinese population. Am J Hypertens. 2013;26:931-938.
13. Fontil V, Bibbins-Domingo K, Nguyen OK, et al. Management of hypertension in primary care safety-net clinics in the United States: a comparison of community health centers and private physicians’ offices. Health Serv Res. 2017;52:807-825.
14. Fontil V, Pletcher MJ, Khanna R, et al. Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010. J Gen Intern Med. 2014;29:468-476.
15. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
16. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
17. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.
18. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9:2-6.
19. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component?based therapy. Congest Heart Fail. 2003;9:324-332.
20. Brixner DI, Jackson KC 2nd, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin. 2008;24:2597-2607.
21. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8:45-50.
22. Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P T. 2008;33:652-666.
23. Hsu CI, Hsiao FY, Wu FL, et al. Adherence and medication utilisation patterns of fixed-dose and free combination of angiotensin receptor blocker/thiazide diuretics among newly diagnosed hypertensive patients: a population-based cohort study. Int J Clin Pract. 2015;69:729-737.
24. Tung YC, Lin YS, Wu LS, et al. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens (Greenwich). 2015;17:51-58.
25. Levi M, Pasqua A, Cricelli I, et al. Patient adherence to olmesartan/amlodipine combinations: fixed versus extemporaneous combinations. J Manag Care Spec Pharm. 2016;22:255-262.
26. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407.
27. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898-909.
28. Xie L, Frech-Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double-and triple-pill combination therapy. Curr Med Res Opin. 2014;30:2415-2422.
29. Grimmsmann T, Himmel W. Comparison of therapy persistence for fixed versus free combination antihypertensives: a retrospective cohort study. BMJ Open. 2016;6:e011650.